# A Study to Evaluate the Effect of Hepatic Impairment on the Single Dose Pharmacokinetics (PK) of Intravenous TAK-954

> **NCT03277274** · PHASE1 · COMPLETED · sponsor: **Takeda** · enrollment: 25 (actual)

## Conditions studied

- Hepatic Impairment
- Healthy Volunteers

## Interventions

- **DRUG:** TAK-954

## Key facts

- **NCT ID:** NCT03277274
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-09
- **Primary completion:** 2018-09-01
- **Final completion:** 2018-09-10
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2019-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03277274

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03277274, "A Study to Evaluate the Effect of Hepatic Impairment on the Single Dose Pharmacokinetics (PK) of Intravenous TAK-954". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03277274. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*